Shopping Cart
- Remove All
- Your shopping cart is currently empty
ERG245, a BCAT1 inhibitor, specifically targets BCAT1 activity to enhance oxidative phosphorylation (OXPHOS) in CD8+ T cells, boosting their cytotoxicity. Additionally, when used alongside Pembrolizumab (anti-PD-1), ERG245 aids in promoting tumor regression. This compound is valuable in immuno-oncology research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | ERG245, a BCAT1 inhibitor, specifically targets BCAT1 activity to enhance oxidative phosphorylation (OXPHOS) in CD8+ T cells, boosting their cytotoxicity. Additionally, when used alongside Pembrolizumab (anti-PD-1), ERG245 aids in promoting tumor regression. This compound is valuable in immuno-oncology research. |
Molecular Weight | 347.2 |
Formula | C17H15BrO3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.